A Double-blind, Randomized, Placebo-controlled Cross Over Study of Inhaled Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis

Trial Profile

A Double-blind, Randomized, Placebo-controlled Cross Over Study of Inhaled Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs OligoG (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Sponsors AlgiPharma
  • Most Recent Events

    • 22 Mar 2017 This trial was completed in Germany (end date:2016-12-16), according to the European Clinical Trials Database record.
    • 26 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Apr 2017.
    • 26 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top